Conditions: Lung Neoplasms
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 319
Healthy volunteers: no

Brief summary:
This is a randomised, open-label, phase IIb trial of afatinib to compare to gefitinib in first-line treatment setting with patients who are having epidermal growth factor receptor mutation positive advanced adenocarcinoma of the lung.

Detailed description:

Arms:
arm 1: afatinib once daily. arm 2: gefitinib once daily

Interventions: intervention 1: Afatinib intervention 2: gefitinib
Intervention descriptions: intervention 1: afatinib once daily intervention 2: Gefitinib once daily

Protocol document: